


AMENDMENT



Please amend the claims as follows:

SUB
F1

1. A method to prepare an isolated nucleic acid molecule comprising a nucleotide sequence encoding at least one of the variable regions of the α and β chains of a non-human TCR which TCR is [human HLA-restricted and] specific for a tumor-associated antigen (TAA) selected from Her-2/neu, RAS, p53, tyranase, MART, Gp100, Mage, Bage and MUC-1, which method comprises

cloning or amplifying a nucleic acid molecule [containing said] encoding nucleotide sequence isolated from an HLA restricted cytotoxic T lymphocytes (CTL) prepared by [a method which comprises]

1

immunizing a transgenic non-human [vertebrate] mammal or avian species, [which is] modified so as to express at least one human HLA antigen, with an effective amount of said [tumor-associated antigen (TAA)] so as to effect the production in said mouse of] to produce the HLA restricted cytotoxic T lymphocytes which display [human HLA-restricted] TCR specific for said TAA in amounts sufficient to Lys tumor cells having the TAA and which contain said nucleic acid molecules [comprising nucleotide sequences encoding said variable regions of the α and β chains of said TCR], [and] recovering said CTL and isolating said nucleic acid molecules therefrom.

2. (Amended) The method of claim 1 wherein said HLA antigen is [a] A2.

3. (Amended) The method of claim 1 wherein said [non-human vertebrate] mammal is a mouse.

SUB
G3

4.(Amended) The method of claim 3 wherein [said amplifying is effected by] a polymerase chain reaction using primers derived from murine TCR is used to amplify said nucleic acid molecule.